Appropriate imaging modalities for screening, staging, and surveillance of patients with suspected and documented metastatic disease to bone include 99m Tc bone scanning, MRI, CT, radiography, and 2-[ 18 F]fluoro-2-deoxyglucose-PET. Clinical scenarios reviewed include asymptomatic stage 1 breast carcinoma, symptomatic stage 2 breast carcinoma, abnormal bone scan results with breast carcinoma, pathologic fracture with known metastatic breast carcinoma, asymptomatic well-differentiated and poorly differentiated prostate carcinoma, vertebral fracture with history of malignancy, non-small-cell lung carcinoma staging, symptomatic multiple myeloma, osteosarcoma staging and surveillance, and suspected bone metastasis in a pregnant patient. No single imaging modality is consistently best for the assessment of metastatic bone disease across all tumor types and clinical situations. In some cases, no imaging is indicated. The recommendations contained herein are the result of evidence-based consensus by the ACR Appropriateness Criteria ® Expert Panel on Musculoskeletal Radiology.
nonspecific. After an abnormality has been detected, it should be x-rayed to make sure it does not represent a benign process such as osteoarthritis, inflammatory arthritis, or fracture [6] . One of the major advantages of radionuclide bone scanning is that it allows for a totalbody survey. This is important because approximately 13% of metastatic lesions occur in the appendicular skeleton in regions that are usually not included on a skeletal survey [7] . Krishnamurthy et al [7] pointed out that most metastatic skeletal lesions could be asymptomatic and that serum alkaline phosphatase level is a poor indicator of early metastases. Highly aggressive metastases may show "cold" or photopenic areas on a bone scan. Multiple myeloma can frequently show photopenic lesions or negative bone scan results [8, 9] . Bone scans are also insensitive in detecting skeletal lesions due to Langerhans cell histiocytosis (histiocytosis X), and radiographic surveys are recommended for patients with this disease [10, 11] . Diffuse bony metastasis may present with a pattern of intense uniform radionuclide uptake (superscan), which can be misinterpreted as negative findings.
Solitary sites of increased radionuclide uptake in patients with known malignancy are a common occurrence, and they could pose a diagnostic problem because of the nonspecific nature of these abnormalities on bone scintigraphy. On the other hand, Boxer et al [12] reported that approximately 21% of patients with breast cancer relapsed with solitary bone lesions, most commonly in the spine. The spine was the most common site for both solitary and multiple metastases. Tumeh et al [13] reported that solitary rib metastases in cancer patients are uncommon and that 90% of "hot" rib lesions on bone scanning are due to benign causes. A solitary sternal "hot" lesion in a patient with breast carcinoma has an 80% probability of being due to metastatic disease [14] . When a patient with a known primary tumor develops a solitary lesion on a bone scan, further diagnostic evaluation should be undertaken, starting with radiography and, if that is not diagnostic, proceeding to CT, MRI, or even biopsy [15, 16] . Some authors advocate single-photon emission CT (SPECT) imaging as an ef- fective method for differentiating malignant from benign lesions in the spine [17] .
Breast Cancer
In stage 1 breast carcinoma, in which the results of bone scintigraphy are usually negative, most authorities believe that routine baseline and follow-up bone scans are probably unwarranted because of the very low true-positive yield [18, 19] . The panel does not recommend any imaging studies of the skeleton in asymptomatic patients with stage 1 carcinoma of the breast when they present initially (see Variant 1) . Bone scanning, FDG-PET [20, 21] , and PET/CT [22, 23] have been shown to be useful in the preoperative staging and postoperative follow-up of stages 2, 3, and 4 breast carcinoma.
If a patient with stage 2 breast carcinoma presents with back and hip pain, the panel recommends radiography of the back and hip and radionuclide bone scanning (see Variant 2) . Other studies may be needed depending on the results of radiography and bone scanning. In patients with known breast carcinoma who are discovered to have a single "hot" area in the spine on bone scanning, the panel recommends radiography of the "hot" area. If radiographic results are negative, the panel recommends MRI (see Variant 3) . For lesion localization and needle guidance, a CT scan is recommended if a needle biopsy is warranted. The panel recommends adding SPECT imaging if the results of planar radionuclide bone scanning are equivocal. In patients discovered to have multiple "hot" lesions in the spine, the panel recommends radiography of these "hot" lesions; MRI is also recommended if radiographic results are negative (see Variant 4) . A CT scan becomes necessary if a needle biopsy is to be performed.
For a "hot" lesion of the sternum in a patient with known breast carcinoma, the panel recommends radiography, followed by MRI, to help in the diagnosis (see Variant 5) . MRI should be performed with the patient prone to minimize respiratory artifacts, and the use of an opposed-phase (also referred to as in and out of phase) sequence is suggested to best assess for marrow replacement by tumor. Computed tomography is useful for localization if fine-needle aspiration or core biopsy is required.
Long Bone Fracture
In a patient with known metastatic carcinoma presenting with a pathologic fracture of a long bone on radiography, the panel recommends a radionuclide bone scan to look for other metastatic sites in the skeleton (see Variant 6).
Prostate Cancer
Studies have shown that for staging and follow-up of patients with prostate carcinoma, radionuclide bone scans are not necessary unless the prostate specific antigen (PSA) level is Ն20 ng/mL or the primary tumor is poorly differentiated [24] [25] [26] [27] . For routine staging purposes (no bone pain), the panel agrees with these studies (see Variant 7). However, the panel recommends a radionuclide bone scan for patients with prostate-specific antigen levels not Ͼ20 ng/mL or poorly differentiated primary tumors (see Variant 8) .
Non-small-cell Lung Cancer
In patients with non-small-cell carcinoma of the lung, bone is one of the most common sites for early extrathoracic spread. Some of these bony metastases are asymptomatic. The exclusion of bone metastases is important in the initial preoperative staging of lung cancer, although it is not clear from the literature whether bone scans should be performed routinely or only when clinical indicators suggest skeletal metastases [28] [29] [30] . The panel currently recommends a radionuclide bone scan of the skeleton in patients coming for staging after needle biopsy of lung nodules revealed non-small-cell carcinomas (see Variant 9) . However, in patients with nonsmall-cell carcinoma of the lung who have undergone or will be undergoing FDG-PET studies as part of their initial workup, radionuclide bone scanning is not necessary [1, 2] . The current PET literature has significant variability due to differing study quality and imaging techniques used, but this technique has the potential to improve the accuracy of non-small-cell lung carcinoma tumor staging, especially for bone metastases [31] .
Primary Bone Tumors
Bone metastases are very uncommon at initial presentation in patients with primary malignant bone tumors; therefore, radionuclide bone scanning is not indicated. Bone scanning has been shown not to be useful in differentiating between benign and malignant lesions or in defining the local extent of a malignant tumor reliably [32, 33] . Osteosarcoma is probably the only exception; although the yield of imaging for metastases at the time of diagnosis is small, the presence of an occasional metastasis could substantially affect the treatment of the patient [34, 35] . The panel concurs with these reports, and it recommends radionuclide bone scanning for patients with osteosarcoma at presentation for staging (see Variant 10) . In patients with osteosarcoma who have received adjuvant chemotherapy, 16% may develop asymptomatic osseous metastasis before lung metastasis; therefore, some authors suggest bone scans for routine follow-up [34, 35] . The panel concurs with these reports, and it recommends radionuclide bone scanning for patients with osteosarcoma at follow-up and after tumor resection with clear margins and chemotherapy (see Variant 11) . FDG-PET has not been proven to replace chest CT and bone scanning as a staging modality for osteosarcoma [36] .
Other Cancers
In patients with cancers that rarely metastasize to bonesuch as cervical, endometrial, bladder, and gastrointestinal tract tumors-baseline scans are obtained only when the disease is advanced [37] . There is no consensus in the literature about the timing of follow-up scans in asymptomatic patients. Some authors have suggested bone scans every 6 months for 1 year and then every 2 years. In clinical practice, most medical and radiation oncologists request follow-up bone scans only (1) in asymptomatic patients with evidence of progressive disease (ie, rising carcinoembryonic antigen or alkaline phosphatase values), (2) for restaging the disease in patients with local recurrence, and (3) in patients with symptoms that are potentially of osseous origin [37] .
Radiography is frequently used to screen for metastatic sites in multiple myeloma and Langerhans cell histiocytosis (histiocytosis X), but generally it is considered insensitive to screen for asymptomatic metastases [8] [9] [10] [11] . In patients with multiple myeloma who present with acute low-back pain, the panel recommends radiography of the lumbosacral spine or bone survey if the interval since the last bone survey is long (see Variant 12) . Magnetic resonance imaging is useful in patients with neurologic findings or to better characterize the bone marrow. The panel believes that the only time when radionuclide bone scanning (with or without SPECT) would be needed in cases of multiple myeloma is when 89 Sr treatment is being considered.
Vertebral Column
The vertebral column deserves special consideration. It is the most common site of skeletal metastasis, and cord compression from metastasis is among the most dreaded complications of cancer [12] . Magnetic resonance imaging has proven advantages over all other imaging modalities, including myelography and CT myelography [6, 16] (see Variant 13) . One limitation of MRI has been its inability to consistently differentiate an acute traumatic or acute osteopenic compression fracture from a pathologic fracture. The use of diffusion-weighted MRI has been shown to be effective in differentiating benign osteopenic vertebral collapse from malignant collapse, but the efficacy of this technique is still controversial, and it has not gained widespread use [38] [39] [40] [41] [42] . The role of FDG-PET and FDG-PET/CT has been assessed in metastatic disease of the spine. In patients with lung cancer, studies have shown that FDG-PET has better specificity than bone scans using 99m Tc methylene diphosphonate tracer but similar sensitivity for detecting osseous metastatic disease [1, 2] . Additionally, FDG-PET/CT has better specificity for detecting metastatic involvement of the spine than FDG-PET. FDG-PET/CT allows precise localization of bone lesions and associated soft-tissue involvement with potential neurologic significance [4] .
As MRI sequences continue to become faster, there is emerging evidence showing that whole-body MRI is feasible and that it can replace bone scintigraphy for detecting metastatic bone disease. Proponents of this technique indicate that whole-body MRI is more sensitive and more specific than bone scintigraphy or PET [43, 44] . In addition to bone metastases, whole-body MRI can demonstrate silent metastases in the brain, lungs, and liver [45]. Whole-body MRI is also comparable in cost to bone scintigraphy [46] . No ionizing radiation is involved with whole-body MRI, making it especially suited for pregnant patients with suspected bony metastasis [3] (see Variant 14) .
Depending on whether the lesion is lytic, blastic, or associated with a soft-tissue mass, fine-needle aspiration or core biopsy can be used to arrive at a definitive diagnosis in patients suspected of having metastasis of known or unknown origin. Needle biopsy is also helpful in suspected tumor recurrence and to differentiate metastasis from osteonecrosis in previously irradiated bone [47] [48] [49] [50] .
SUMMARY
• Radionuclide bone scanning is the most widely used primary imaging examination for detecting osseous metastasis.
• After an abnormality has been detected, radiographs should be obtained to make sure the abnormality does not represent a benign process.
• If radiography is not diagnostic, additional lesion workup with MRI, CT, SPECT, or FDG-PET/CT is highly variable and should be based on the clinical situation and lesion location.
ANTICIPATED EXCEPTIONS
Nephrogenic systemic fibrosis is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It seems to be related to both underlying severe renal dysfunction and the administration of gadoliniumbased contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rates (ie, Ͻ30 mL/min/1.73 m 2 ), and almost never in other patients. There is growing literature regarding nephrogenic systemic fibrosis. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk and to limit the type and amount in patients with estimated glomerular filtration rates Ͻ30 mL/min/ 
RELATIVE RADIATION LEVEL INFORMATION
Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level indication has been included for each imaging examination. The relative radiation levels are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure ( ‫ء‬The relative radiation level assignments for some examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, the region of the body exposed to ionizing radiation, the imaging guidance that is used). The relative radiation levels for these examinations are designated as "NS" (not specified).
